Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + PEG + RBV in Treatment-Experienced HCV Genotype 2/3
NCT01808248Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir in hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response at 12 Weeks and Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s) up to 12 weeks. Started Feb 2013; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01808248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808248.